Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECT: Abiraterone and Atorvastatin in Oligometastatic Prostate Cancer
NCT05404139Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- May 2023
- Primary completion
- Feb 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone, atorvastatin in prostate cancer (PCa), sponsored by University Health Network. Started May 2023; status: recruiting.
02
Drugs
abirateroneatorvastatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05404139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05404139.